SCHEMBL1344657

SCHEMBL1344657

CC(=O)Nc1cc(Cc2sccc2-c2nnc(Nc3ccc(Cl)cc3)s2)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
P2RX3 P56373 3/20 0.38
MAPK14 Q16539 2/20 0.38
PIK3C3 Q8NEB9 1/20 0.37
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
HTT P42858 3/20 0.37
KDM4E B2RXH2 2/20 0.37
BLM P54132 1/20 0.37
MCL1 Q07820 1/20 0.37
MAPT P10636 4/20 0.36
PTGS2 P35354 1/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
PIK3CG P48736 1/20 0.35
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346590 0.91 LMNA (0.42) SMN1; SMN2RAB9ANPC1MAPK14HTT
SCHEMBL1344909 0.91 PIP5K1C (0.41) SMN1; SMN2RAB9ANPC1MAPK14PIK3C3
SCHEMBL1346459 0.89 NR3C2 (0.45) MAPK14MAPT
SCHEMBL1346935 0.87 BRAF (0.44) MAPT
SCHEMBL1346766 0.84 NR3C2 (0.46) MAPK14PIK3C3MAPTKMT2AMEN1
SCHEMBL1346528 0.83 CA12 (0.39) SMN1; SMN2P2RX3KDM4EMAPTALDH1A1
SCHEMBL1344767 0.80 FLT1 (0.46) SMN1; SMN2RAB9ANPC1HTTKDM4E
SCHEMBL1344651 0.79 KMT2A (0.47) P2RX3HTTMAPTKMT2AMEN1
SCHEMBL1344656 0.74 GSK3B (0.44) RAB9AKDM4EALDH1A1FLT1KDR
SCHEMBL1346639 0.73 PIK3CD (0.42) SMN1; SMN2RAB9ANPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US claimed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US claimed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP claimed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY FLT4, VEGFA, FLT1 SMN1; SMN2 4393/4885RAB9A 2350/4885NPC1 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.